RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised

Key Takeaways Roche's sales hit CHF 45.9B for the first nine months of 2025, up 7% at constant exchange ratesPharma sales grew 9% to CHF 35.5B on strong demand for key drugs like Phesgo and Hemlibra.Roche raised its 2025 EPS growth outlook. Swiss pharma giant Roche Holding AG (RHHBY) reported sales of CHF 14.9 billion for the third quarter of 2025, up 6% year over year at constant exchange rates (CER), driven by the strong demand for its drugs.The company reports under two divisions — Pharmaceuticals and Di ...